Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the American College of Cardiology

• Publication date

  2005-07-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JACC.2005.03.044PMID 15992646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• treatment of

  2005cited by this paper
• A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.

  2005cited by this paper
• Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats

  2004cited by this paper
• A randomised controlled trial of caregiver training in stroke patients

  2004cited by this paper
• Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure

  2004cited by this paper
• What are the clinical consequences of anemia in patients with chronic heart failure?

  2004cited by this paper
• Cardioprotective Effects of Erythropoietin in the Reperfused Ischemic Heart

  2004cited by this paper
• Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion

  2004influential reference
• Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia‐reperfusion injury

  2004cited by this paper
• Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury

  2004cited by this paper
• Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats

  2004cited by this paper
• Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.

  2004cited by this paper
• Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.

  2004influential reference
• Erythropoietin in cardiovascular diseases.

  2004cited by this paper
• Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury

  2004cited by this paper
• Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin.

  2003cited by this paper
• Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

  2003influential reference
• Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure

  2003cited by this paper
• Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats

  2003cited by this paper
• Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

  2003cited by this paper
• The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and Abnormalities

  2003cited by this paper
• A novel protective effect of erythropoietin in the infarcted heart.

  2003influential reference
• Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction.

  2003cited by this paper
• Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Rapid Communication

  2003cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Small Amounts of &agr;-Myosin Heavy Chain Isoform Expression Significantly Increase Power Output of Rat Cardiac Myocyte Fragments

  2002cited by this paper
• Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

  2002cited by this paper
• Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases

  2002cited by this paper
• Erythropoietin and VEGF exhibit equal angiogenic potential.

  2002cited by this paper
• Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats

  2002cited by this paper
• Apoptosis of Endothelial Cells Precedes Myocyte Cell Apoptosis in Ischemia/Reperfusion Injury

  2001cited by this paper
• The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.

  2001cited by this paper
• Increased Cerebral Infarct Volumes in Polyglobulic Mice Overexpressing Erythropoietin

  2001cited by this paper
• Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

  2001cited by this paper
• Blood transfusion in elderly patients with acute myocardial infarction.

  2001cited by this paper
• Capillary/myocyte mismatch in the heart in renal failure--a role for erythropoietin?

  2000cited by this paper
• Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.

  2000cited by this paper
• Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

  1999influential reference
• In vivo evidence that erythropoietin protects neurons from ischemic damage.

  1998cited by this paper
• Early captopril treatment inhibits DNA synthesis in endothelial cells and normalization of maximal coronary flow in infarcted rat hearts.

  1998cited by this paper
• Age‐dependent changes in myosin composition correlate with enhanced economy of contraction in guinea‐pig hearts

  1998cited by this paper
• Erythropoietin Potentiates Thrombus Development in a Canine Arterio-Venous Shunt Model

  1997cited by this paper
• The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats.

  1996cited by this paper
• Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding.

  1996cited by this paper
• Recombinant human erythropoietin stimulates angiogenesis in vitro.

  1995cited by this paper
• Erythropoietin receptor mRNA expression in human endothelial cells.

  1994cited by this paper
• Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).

  1993cited by this paper
• Progressive ventricular remodeling in rat with myocardial infarction.

  1991cited by this paper
• A dose-dependent effect of recombinant erythropoietin on the reticulocyte population of rats

  1989cited by this paper

• Erythropoietin supplementation induces dysbiosis of the gut microbiota and impacts mucosal immunity in a non-diseased mouse model

  2025cites this paper
• Neuronal nitric oxide synthase required for erythropoietin modulation of heart function in mice

  2024cites this paper
• Therapeutic Evaluation of Recombinant Human Erythropoietin (rhEPO) In Isoproterenol Induced Myocardial Infarction in Wistar Rats

  2024cites this paper
• Anemia in Heart Failure: A Perspective from 20-Year Bibliometric Analysis

  2024cites this paper
• Erythropoietin Gel as an adjunct to Xenograft in the Surgical Management of Intrabony Periodontal Defects :A Randomized Controlled Clinical Study

  2024cites this paper
• The role of erythropoietin in the regulation of cardiac tolerance to impact of ischemia and reperfusion

  2023cites this paper
• Cell or cell derivative-laden hydrogels for myocardial infarction therapy: from the perspective of cell types.

  2023cites this paper
• Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction

  2022cites this paper
• Does Hypoxia and Stress Erythropoiesis Compromise Cardiac Function in Healthy Adults? A Randomized Trial

  2022cites this paper
• Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms

  2022cites this paper
• Healing the Broken Hearts: A Glimpse on Next Generation Therapeutics

  2022cites this paper
• A novel substrate based on electrospun polyurethane nanofibers and electrosprayed polyvinyl alcohol microparticles for recombinant human erythropoietin delivery.

  2021cites this paper
• Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine

  2021cites this paper
• Anemia in Acute Coronary Syndrome: An Overview

  2021cites this paper
• A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats

  2021cites this paper
• CARDIOPROTECTIVE ACTIVITIES OF QUERCETIN AND RUTIN IN SPRAGUE DAWLEY RATS TREATED WITH 5-FLUOROURACIL

  2020cites this paper
• Erythropoietin supports the growth and function of Sca-1+ stem cells and promotes myocardial infarction repair in mice

  2020cites this paper
• Application of Erythropoietin in Chronic Heart Failure Treatment.

  2020cites this paper
• The Many Facets of Erythropoietin Physiologic and Metabolic Response

  2020cites this paper
• Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction

  2020cites this paper
• Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain and bone.

  2020cites this paper
• Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?

  2019cites this paper
• Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

  2019cites this paper
• Effects of Epoetin Alfa in STEMI patients Long term effects of Epoetin Alfa in patients with ST- elevation myocardial infarction

  2019cites this paper
• Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG).

  2019cites this paper
• University of Groningen Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction

  2019cites this paper
• Development of nanomedicines for inflammation disorders : evaluation of pharmacological efficacy on preclinical models

  2019cites this paper
• Chitosan/silk fibroin modified nanofibrous patches with mesenchymal stem cells prevent heart remodeling post-myocardial infarction in rats.

  2018cites this paper
• Erythropoietin reduces collagen deposition after myocardial infarction but does not improve cardiac function.

  2018cites this paper
• Alternative Erythropoietin Receptors in the Nervous System

  2018cites this paper
• Erythropoietin-Loaded Nanofibrous Patch for Regeneration of Infarcted Myocardium

  2017cites this paper
• NATURAL MEANS OF AUGMIENTING ENDOGENOUS STEM CELL NUMBERS CROSS-REFERENCE TO RELATED APPLICATIONS

  2017cites this paper
• Nanoplumbers: biomaterials to fight cardiovascular diseases

  2017cites this paper
• University of Groningen Anemia and erythropoietin in cardiovascular disease

  2017cites this paper
• Perioperativna zaščita z eritropoetinom centralnega živčnega sistema, ledvic in srca pri operacijah na srcu

  2017cites this paper
• From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities

  2017cites this paper
• University of Groningen From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities Suthahar,

  2017cites this paper
• Angiogenic growth factors in myocardial infarction: a critical appraisal

  2017cites this paper
• Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

  2017cites this paper
• Study of the Possible Cardioprotective Effects of Erythropoietin in Diabetic and Uremic Cardiomyopathy in Rats

  2017cites this paper
• Differences in the association between behavior and neutrophil gelatinase-associated lipocalin in male and female rats after coronary artery ligation.

  2016cites this paper
• Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis

  2016cites this paper
• Prognostic significance of endogenous erythropoietin in long‐term outcome of patients with acute decompensated heart failure

  2016cites this paper
• Highlights of the Year in JACC2005

  2016cites this paper
• Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery

  2016cites this paper
• Cardioprotective Effect of Erythropoietin on Isoprenaline Induced Myocardial Infarction in Rats

  2016cites this paper
• RECOMBINANT ERYTHROPOIETIN MITIGATES REPERFUSION INJURY IN NEONATAL RAT CARDIOMYOCYTES BY NOVEL MULTIPLE SIGNALLING PATHWAYS

  2016cites this paper
• Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease.

  2016cites this paper
• Postoperative cognitive dysfunction and neuroinflammation; Cardiac surgery and abdominal surgery are not the same.

  2016cites this paper
• Endothelial Progenitor Cells Predict Long-Term Mortality in Hemodialysis Patients

  2016cites this paper
• Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review.

  2015cites this paper
• Contemporary perspective on endogenous myocardial regeneration.

  2015cites this paper
• Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction

  2015cites this paper
• Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology

  2015cites this paper
• Saphenous Vein Graft Disease Is Associated with a Low Serum Erythropoietin Level

  2015cites this paper
• The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI

  2014cites this paper
• Papel da eritropoetina na atenuação da fibrose miocárdica

  2014cites this paper
• An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium

  2014cites this paper
• Erythropoietin Therapy for Heart Failure

  2014cites this paper
• The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions

  2014cites this paper
• Analysis of the Protective Properties of Erythropoetin and Nicorandil on the Basis of the Model of the Retina Ischemia/Reperfusion.

  2014cites this paper
• The Role of Inflammation in Myocardial Infarction

  2014cites this paper
• Die Wirkung von Erythropoietin auf die Thrombozytenfunktion im akuten Myokardinfarkt

  2014cites this paper
• Erythropoietin and the heart: physiological effects and the therapeutic perspective.

  2014cites this paper
• Anemia and erythropoietin in cardiovascular disease

  2014cites this paper
• Myocardial infarction: cardioprotection by erythropoietin.

  2013cites this paper
• Erythropoietin and engineered innate repair activators.

  2013cites this paper
• Erythropoietin Combined with ACE Inhibitor Prevents Heart Remodeling in 5/6 Nephrectomized Rats Independently of Blood Pressure and Kidney Function

  2013cites this paper
• Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

  2013cites this paper
• Erythropoetin in der Plastischen Chirurgie

  2013cites this paper
• Erythropoietin and Its Role in Regenerative Medicine

  2013cites this paper
• Outcome after percutaneous coronary intervention

  2013cites this paper
• Erythropoietin in cardiac disease: effective or harmful?

  2013cites this paper
• A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial

  2013cites this paper
• Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis

  2013cites this paper
• Therapy for the Coronary Circulation

  2013cites this paper
• Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.

  2013influential citation
• Cell microencapsulation for therapeutic purposes: towards greater control over biocompatibility

  2012cites this paper
• Asialoerythropoietin, a Nonerythropoietic Derivative of Erythropoietin, Displays Broad Anti-Heart Failure Activity

  2012cites this paper
• Erythropoietin: a future therapy for failing hearts?

  2012cites this paper
• Cardiac Tissue Engineering

  2012cites this paper
• Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

  2012cites this paper
• Anemia and Iron Deficiency in Heart Failure

  2012cites this paper
• The role of galectin-3 in cardiac remodeling and fibrogenesis

  2012cites this paper
• Terapia combinada com eritropoetina e fator estimulante da colônia de granulócitos em um modelo de infarto agudo do miocárdio

  2012cites this paper
• The role of galectin-3 in cardiac remodeling and fibrogenesis

  2012cites this paper
• PLEOTROPIC CARDIOPROTECTIVE EFFECTS OF ERYTHROPOIETIN

  2012cites this paper
• Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis

  2012cites this paper
• Pressure overload induces early morphological changes in the heart.

  2012cites this paper
• Angiogenic effects of erythropoietin.

  2012cites this paper
• Temporal Changes in Phosphatidylserine Expression and Glucose Metabolism after Myocardial Infarction: An in Vivo Imaging Study in Mice

  2012cites this paper
• Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.

  2012cites this paper
• Human mesenchymal stromal cells could deliver erythropoietin and migrate to the basal layer of hair shaft when subcutaneously implanted in a murine model.

  2012cites this paper
• Erythropoietin in the critically ill: do we ask the right questions?

  2012cites this paper
• Cotreatment with Darbepoetin and Granulocyte Colony-Stimulating Factor is Efficient to Recruit Proangiogenic Cell Populations in Patients with Acute Myocardial Infarction

  2012cites this paper
• Living cardiac patch: the elixir for cardiac regeneration

  2012cites this paper
• Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest.

  2012cites this paper
• Induction of Hypoxia Inducible Factor Rather than Modulation of Collagen Metabolism Improves Cardiac Function and Reduces Left Ventricular Hypertrophy after Aortocaval Shunt in Rats

  2012cites this paper
• Cardiorenal interaction : experimental and clinical studies

  2012cites this paper
• The role of erythropoietin in the "stroke belt" phenomenon.

  2012cites this paper